Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

DMSO-Free Cryopreservation of Human T Lymphocytes in Chemically Defined Systems

DMSO-Free Cryopreservation of Mesenchymal Stem Cells in Chemically Defined Systems

Exbumin – Reconstitution Application Note

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

Expansion of Adherent HEK293T Cells in Flasks in Chemically Defined Cell Culture Media

Lentivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield

Maintaining Viable Cell Count in Primary T Cells During Cell Washing Using Optibumin®

OptiVERO – Expansion of VERO Cells Without Serum in Chemically Defined Cell Culture Media

OptiVERO – Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media Application Note

OptiVERO – Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media

Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells

Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Transient Transfection Protocol – Enhancement of Transfection Efficiency Using Recombinant Transferrin with Serum-Free HEK293 Media

Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells Application Note

Blog

3 Takeaways from the World Vaccine Congress 2018

ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy

BIO 2018: The Emergence of Gene & Cell Therapy

BIO Europe 2018: From Lab Innovations to Commercial Realities

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Controlling Impurities in Cell Culture Media

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Evolving Challenges in Closed-System Biomanufacturing

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

Happy Holidays from the InVitria Team!

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

InVitria at the American Association of Immunologists 2018 Conference

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

InVitria’s Top Insights from ISCT 2018 – Montreal

Join InVitria at ECI 2019

Join InVitria at Phacilitate 2019

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Phacilitate 2019 and World Stem Cell Summit

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

Formulation and Production of a Blood-free and Chemically Defined Virus Production Media for VERO Cells

Posters

Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin

Cryoprotectant Additives, Including rHSA, Improve iNK and iT Cell Health & Viability During Cryopreservation

DMSO-Free Cryopreservation Formulation As An Alternative Cryopreservation Method For Cell-based Therapies

Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

Product Brochures

2020 Product Catalog

ITSE AF – Brochure

Lysobac – Brochure – E.Coli Lysis

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

SDS

Exbumin – Safety Data Sheet

ITSE AF – Safety Data Sheet

Lysobac – Safety Data Sheet

Lysosure – Safety Data Sheet

Optibumin – Safety Data Sheet

Cellastim S – Safety Data Sheet

Use Guidelines

OptiFRZ Guidelines for Use

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

Lysobac – Guidelines for Use

Optiferrin – Guidelines for Use

OptiVERO – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation

Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Emergence of Blood-Free Recombinant Human Albumin

Optiferrin – Recombinant Transferrin an Iron Transport Protein in Cell Culture Media

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin

Process Optimization for Lentivirus Production in the iCELLis® Nano Using a Chemically Defined, Animal Component Free HEK293 Media

VERO Expansion in the iCellis® Bioreactor with Chemically Defined and Blood Free Virus Production Media